Market Overview

Aegerion Pharmaceuticals Announces Presentation at the 31st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 3, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the 31st Annual J.P. Morgan Healthcare Conference in San Francisco. Marc Beer, CEO of Aegerion, is scheduled to present on Tuesday, January 8, 2013 at 2:00 pm PT (5:00 pm ET).

The presentation will be webcast live and may be accessed for up to 14 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com.

The Aegerion Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16441

CONTACT: Aegerion Pharmaceuticals, Inc. Michael Lawless, VP, IR 857-242-5028

Aegerion Pharmaceuticals, Inc. Logo

 

Around the Web, We're Loving...

Get Benzinga's Newsletters